

# *LKB1 is the gatekeeper of carotid body chemosensing and the hypoxic ventilatory response*

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open access

MacMillan, S., Holmes, A. P., Dallas, M. L. ORCID: <https://orcid.org/0000-0002-5190-0522>, Mahmoud, A. D., Shipston, M. J., Peers, C., Hardie, D. G., Kumar, P. and Evans, A. M. (2022) LKB1 is the gatekeeper of carotid body chemosensing and the hypoxic ventilatory response. *Communications Biology*, 5. 642. ISSN 2399-3642 doi: <https://doi.org/10.1038/s42003-022-03583-7> Available at <https://centaur.reading.ac.uk/106401/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1038/s42003-022-03583-7>

Publisher: Nature Research

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).






[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

**CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

## LKB1 is the gatekeeper of carotid body chemosensing and the hypoxic ventilatory response

Sandy MacMillan <sup>1,5</sup>, Andrew P. Holmes<sup>2,5</sup>, Mark L. Dallas <sup>3</sup>, Amira D. Mahmoud<sup>1</sup>, Michael J. Shipston <sup>1</sup>, Chris Peers<sup>6</sup>, D. Grahame Hardie <sup>4</sup>, Prem Kumar<sup>2</sup> & A. Mark Evans <sup>1</sup>✉

The hypoxic ventilatory response (HVR) is critical to breathing and thus oxygen supply to the body and is primarily mediated by the carotid bodies. Here we reveal that carotid body afferent discharge during hypoxia and hypercapnia is determined by the expression of Liver Kinase B1 (LKB1), the principal kinase that activates the AMP-activated protein kinase (AMPK) during metabolic stresses. Conversely, conditional deletion in catecholaminergic cells of AMPK had no effect on carotid body responses to hypoxia or hypercapnia. By contrast, the HVR was attenuated by LKB1 and AMPK deletion. However, in LKB1 knockouts hypoxia evoked hypoventilation, apnoea and Cheyne-Stokes-like breathing, while only hypoventilation and apnoea were observed after AMPK deletion. We therefore identify LKB1 as an essential regulator of carotid body chemosensing and uncover a divergence in dependency on LKB1 and AMPK between the carotid body on one hand and the HVR on the other.

<sup>1</sup>Centre for Discovery Brain Sciences, Hugh Robson Building, University of Edinburgh, Edinburgh EH8 9XD, UK. <sup>2</sup>School of Biomedical Sciences, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK. <sup>3</sup>School of Pharmacy, University of Reading, Reading RG6 6UB, UK. <sup>4</sup>Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK. <sup>5</sup>These authors contributed equally: Sandy MacMillan, Andrew P. Holmes. <sup>6</sup>Deceased: Chris Peers. ✉email: [mark.evans@ed.ac.uk](mailto:mark.evans@ed.ac.uk)

The hypoxic ventilatory response (HVR) delivers compensatory increases in the ventilatory drive where there are deficiencies in oxygen availability. The HVR is initiated by increases in afferent fibre discharge from the carotid bodies, the primary peripheral arterial chemoreceptors of mammals that are located within the bifurcations of the carotid artery, ideally situated to monitor blood flow to the brain. Within the carotid body falls in arterial  $PO_2$  (and increases in arterial  $PCO_2$ ) are sensed directly by carotid body type I cells, where consequent depolarisation elicits the exocytotic release of ATP that mediates increases in chemoafferent discharge to the respiratory central pattern generators in the brainstem<sup>1–3</sup>.

We recently showed that in addition to regulating metabolic homeostasis in a cell-autonomous manner<sup>4</sup> the AMP-activated protein kinase (AMPK) facilitates the HVR and thus oxygen and energy (ATP) supply to the whole body<sup>5</sup>. In doing so, we demonstrated that AMPK acts not at the level of the carotid bodies as one would predict but downstream at the brainstem. Briefly, conditional deletion of AMPK in catecholaminergic neurons of mice precipitates hypoventilation and apnoea during poikilocapnic hypoxia<sup>5</sup>, which resembles central apnoea of prematurity<sup>6,7</sup> and central sleep apnoea<sup>8</sup> in the neonate and adult humans, respectively. That said, the HVR of these mice is most reminiscent of the HVR observed in premature infants where the hypercapnic hypoxic ventilatory response is similarly conserved<sup>9</sup>. Given such face validity that resembles symptoms in patients, it is important that we identify the mechanism(s) by which AMPK is regulated in the context of the HVR.

The principal pathway of AMPK activation by metabolic stresses is through direct phosphorylation by Liver Kinase B1 (LKB1), which exists in a complex with regulatory proteins STRAD and MO25<sup>10–12</sup>. LKB1 also regulates by direct phosphorylation eleven of the twelve AMPK-related kinases<sup>13</sup>, but in each case this is insensitive to metabolic stresses<sup>14</sup>. Only AMPK is coupled to LKB1 through changes in the cellular AMP:ATP and ADP:ATP ratios<sup>15</sup>, which may be triggered through inhibition of mitochondrial oxidative phosphorylation during hypoxia, as is the HVR<sup>16,17</sup>. Binding of AMP to the AMPK- $\gamma$  subunit increases activity 10-fold by allosteric activation alone, while binding of AMP or ADP triggers increases in phosphorylation of Thr172 on the  $\alpha$  subunit by LKB1 (conferring up to 100-fold further activation) and at the same time reduces Thr172 dephosphorylation<sup>18</sup>. However, alternative AMP-independent mechanisms of AMPK activation have been identified: (i) calcium-dependent Thr172 phosphorylation by the calmodulin-dependent protein kinase CaMKK2<sup>19</sup>; (ii) long-chain fatty acyl-CoA binding to the Allosteric Drug & Metabolite (ADaM) site on the  $\alpha$  subunit<sup>20</sup>; (iii) glucose-deprivation<sup>21</sup>.

Clearly, the most likely path to AMPK activation during hypoxia would be through increases in the AM(D)P:ATP ratio and thus LKB1-dependent phosphorylation. However, the fact that AMPK facilitates the HVR within regions of the brainstem that receive carotid body afferent input responses<sup>5</sup>, rather than at the level of the carotid bodies<sup>1–3</sup>, also suggests a role for the alternative CaMKK2 pathway, which has been proposed to contribute to energy balance regulation by hypothalamic networks<sup>22</sup>.

We set out to examine the mechanism by which AMPK is regulated in the context of the HVR. To this end we employed a three-point assay to assess the relationship between the level of LKB1 expression, carotid body activation during hypoxia and the HVR, by utilising a mouse line which exhibits ~90% global hypomorphic expression of the gene that encodes LKB1 (*Stk11*, hereafter referred to as *Lkb1*)<sup>23,24</sup> and a conditional homozygous LKB1 knockout mouse line derived from this in which 100% *Lkb1* deletion is triggered by Cre expression via the tyrosine hydroxylase (TH) promoter, which restricts *Lkb1* deletion to catecholaminergic cells including therein carotid body type I cells. We compared

outcomes to those observed in mice where CaMKK2 had been deleted globally.

The present investigation not only demonstrates that LKB1, but not CaMKK2, is required for the HVR, but also reveals that the level of LKB1 expression serves an essential role in establishing carotid body function and chemosensitivity. In short, we uncover a divergence in dependency on LKB1 and AMPK between the carotid body on the one hand and the HVR on the other. Adding to this we show that LKB1, but not AMPK, deficiency within catecholaminergic cells precipitates Cheyne-Stokes-like breathing patterns during hypoxia, which are associated with heart failure but of unknown aetiology<sup>25</sup>.


## Results

### LKB1 deficiency augments while homozygous *Lkb1* gene deletion ablates type I cell activation in response to hypoxia.

We confirmed that Cre expression and deletion of the gene encoding LKB1 were targeted to catecholaminergic cells by two means. Firstly, these mice were crossed with a mouse line expressing the Cre-inducible reporter gene Rosa (tdTomato), the expression of which in type I cells was assessed by confocal imaging of acutely isolated and fixed sections of tissue comprising the superior cervical ganglion, carotid artery and carotid body (Fig. 1a; note, TH is expressed by carotid body type I cells, endothelial cells and sympathetic neurons). Then, the absence of LKB1 expression was confirmed in acutely isolated carotid body type I cells by single-cell end-point RT-PCR (Fig. 1b, c and Supplementary Fig. 1); consistent with outcomes for other organs including the brain<sup>23,24</sup> LKB1 expression from homozygous *Lkb1* floxed mice ( $Ct = 31.147 \pm 0.098$ ,  $n = 3$ ) was lower than for TH-Cre mice ( $Ct = 25.139 \pm 0.006$ ,  $n = 3$ ) in whole carotid bodies, although it should be noted that this multi-cellular organ is not representative of pure type I cells.

We next examined the impact of LKB1 deletion on carotid body type I cell function. To this end, we employed TH-Cre mice as the control group, because these mice were used to deliver *Lkb1* deletion in catecholaminergic cells and there was no significant difference between the hypoxic ventilatory response of these mice when compared to the background strain (C57/BL6; Supplementary Fig. 2). Changes in intracellular calcium concentration within isolated type I cells was assessed as an index of their activation by hypoxia, using the ratiometric calcium indicator Fura-2. Hypoxia (mean  $\pm$  SEM  $PO_2 = 20.19 \pm 1.73$  mmHg, ~2%  $O_2$  ( $n = 10$ ); from normoxia ~150 mmHg, ~21%  $O_2$ ) induced a robust increase in Fura-2 fluorescence ratio in type I cells from TH-Cre mice ( $n = 8$ ), which was equivalent to that resulting from voltage-gated calcium influx triggered by membrane depolarisation in response to extracellular application of 50 mM potassium chloride (Fig. 1di, e–g, Supplementary Fig. 3). Surprisingly, outcomes for type I cells from *Lkb1* floxed mice and *Lkb1* knockouts were not only different but opposite. Potassium-evoked calcium transients were markedly augmented in *Lkb1* floxed mice ( $n = 11$ ; Fig. 1dii, e–g and Supplementary Fig. 3), which are hypomorphic with ~90% lower expression of LKB1 globally when compared to wildtype controls<sup>23</sup>. In marked contrast, hypoxia failed to increase intracellular calcium in type I cells from homozygous *Lkb1* knockouts ( $n = 8$ ), where calcium transients evoked by 50 mM potassium chloride were equivalent to controls (Fig. 1diii, e–g).

**LKB1 deficiency attenuates while homozygous *Lkb1* deletion virtually abolishes increases in carotid body afferent discharge during hypoxia and hypercapnia.** Extracellular recordings of single-unit activity from the carotid sinus nerve, showed that increases in afferent discharge frequency during hypoxia were



**Fig. 1** Conditional deletion of *Lkb1* in carotid body type I cells blocks hypoxia-evoked calcium transients. **a** Confocal image shows tdTomato (excitation 555 nm, emission 582 nm) positive type I cells in situ within a section of tissue comprising the carotid body, superior cervical ganglion (SCG) and carotid artery; note endothelial cells and sympathetic neurons express tyrosine hydroxylase (TH). **b** Acutely isolated carotid body type I cells stained for TH and DAPI. **c** Single-cell end-point RT-PCR amplicons for TH and *Lkb1* from acutely isolated adrenal medullary chromaffin cells (WT AMCs) and carotid body type I cells of wildtype (WT CB1 cells) and conditional *Lkb1* knockout mice (*Lkb1* hom KO CB1 cells); NC = negative control (cell aspirant but no reverse transcriptase added); NEC = negative extracellular control (aspirant of extracellular medium). **d** Exemplar records show calcium transients evoked by 50 mM potassium and hypoxia (mean  $\pm$  SEM  $PO_2 = 20.19 \pm 1.73$  mmHg,  $\sim 2\%$   $O_2$ ;  $n = 10$ ) in type I cells isolated from (I) TH-Cre (black;  $n = 8$  different carotid body type I cells), (II) homozygous *Lkb1* homozygous floxed (*Lkb1* hom Fx, blue;  $n = 11$  different carotid body type I cells) and (III) conditional homozygous *Lkb1* hom KO (red,  $n = 8$  different carotid body type I cells) mice. **e-g** Dot plots show mean  $\pm$  SEM F340/F380 ratios for calcium transients evoked by **e** 50 mM potassium, **f** hypoxia, while **g** shows the hypoxic response expressed as a ratio of the response to 50 mM potassium.  $*=p < 0.05$ ,  $**=p < 0.01$ ,  $***=p < 0.0001$ . Replicates taken from  $\geq 3$  different mice.


attenuated in carotid bodies from *Lkb1* floxed mice, and virtually abolished in carotid bodies from *Lkb1* knockouts (Fig. 2a, b).

During normoxia, basal afferent fibre discharge frequency from in vitro carotid bodies of controls (TH-Cre,  $n = 8$ ) was similar to that of homozygous *Lkb1* floxed mice ( $p = 0.38$  by analysis of variance (ANOVA);  $p = 0.17$  by Student's *t* test;  $n = 8$ ; Fig. 2d) that exhibit  $\sim 90\%$  global reductions in LKB1 expression<sup>23</sup>. By contrast, mean basal afferent discharge from carotid bodies of homozygous *Lkb1* knockouts ( $n = 7$ ) was reduced by  $\sim 70\%$  (Fig. 2d) which reached significance by Student's *t* test ( $p < 0.05$  versus TH-Cre) but not by ANOVA ( $p = 0.09$  versus TH-Cre and  $p = 0.06$  vs *Lkb1* floxed).

Reductions in superfusate  $PO_2$  evoked exponential increases in afferent discharge from carotid bodies of controls and *Lkb1* floxed mice. Intriguingly, however, during hypoxia ( $PO_2 \leq 75$  mmHg) peak discharge frequencies of *Lkb1*-floxed mice ( $\sim 90\%$  loss of LKB1 expression) were attenuated by  $\sim 50\%$  relative to controls (TH-Cre;  $p < 0.01$ ; Fig. 2c, e). Furthermore, the  $PO_2$  required to reach a frequency of 5 Hz was lower in the *Lkb1* floxed mice ( $70 \pm 7$  mmHg) compared to TH-Cre controls ( $96 \pm 4$  mmHg,  $p < 0.01$ ; Supplementary Fig. 3), indicative of a delay/lower  $PO_2$  threshold for response initiation. Exponential rate constants were

consistent between TH-Cre and homozygous *Lkb1* floxed mice (Supplementary Fig. 3). By contrast, reductions in superfusate  $PO_2$  evoked little or no increase in afferent discharge from carotid bodies of homozygous *Lkb1* knockouts (Fig. 2c, e;  $p < 0.0001$  versus TH-Cre and  $p < 0.05$  versus *Lkb1* floxed), consistent with the fact that homozygous *Lkb1* deletion abolished type I cell activation during hypoxia. One can only assume that the  $\sim 50\%$  reduction in hypoxia-evoked afferent discharge in carotid bodies isolated from *Lkb1*-floxed mice was due to their  $\sim 90\%$  deficiency in LKB1 expression<sup>23</sup>, despite the fact that hypoxia-evoked calcium transients in isolated type I cells from these mice were augmented relative to controls (see Fig. 1).

Our original assumption had been that LKB1 would primarily function to couple reductions in mitochondrial ATP supply to carotid body type I cell activation and thus carotid body afferent discharge during hypoxia. It was a surprise to find, therefore, that *Lkb1* deletion also attenuated carotid body activation during hypercapnia (Fig. 3a), given that carotid body responses to hypercapnia are generally presumed to be triggered by ion channel mechanisms independent of mitochondrial metabolism<sup>26–29</sup>, although earlier studies had provided pharmacological evidence that pointed to a partial dependence on mitochondria (see




**Fig. 2 Conditional deletion of *Lkb1* in carotid body type I cells attenuates basal and hypoxia-evoked afferent discharge from the carotid body in vitro.**

**a** shows (I) extracellular recordings of chemoafferent discharge versus time during normoxia and hypoxia and (II) frequency-time histograms (inset: single fibre discriminations) for carotid bodies from control (TH-Cre, black), *Lkb1* homozygous floxed (*Lkb1* hom Fx, blue, middle panels) and conditional *Lkb1* homozygous knockout mice (*Lkb1* hom KO, red). **b** Exemplar frequency- $PO_2$  response curves for records shown in **a**. **c** Compares mean  $\pm$  SEM for frequency- $PO_2$  response curves for TH-Cre ( $n=8$  different carotid bodies), homozygous *Lkb1* floxed ( $n=8$  different carotid bodies) and conditional homozygous *Lkb1* knockout ( $n=7$  different carotid bodies) mice. Dot plots show mean  $\pm$  SEM for **d** basal single fibre discharge frequency and **e** peak single fibre discharge frequency during hypoxia. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\*\* $p < 0.0001$ .

Discussion for further details)<sup>30</sup>.  $CO_2$ -sensitivity (which is linear between 40 and 80 mmHg) was largely preserved in the *Lkb1* floxed mice ( $n=6$ ,  $p=0.38$  versus TH-Cre) but was virtually abolished in carotid bodies from homozygous *Lkb1* knockouts ( $n=4$ ) when compared to TH-Cre ( $p < 0.01$  versus TH-Cre;  $p < 0.06$  versus *Lkb1* floxed;  $n=7$ ; Fig. 3b, c).

In stark contrast, and consistent with our preliminary findings<sup>5</sup>, extracellular recordings of single-unit activity from the carotid sinus nerve, showed that increased carotid body afferent responses to hypoxia in the *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous knockouts ( $n=8$ ) remained comparable to TH-Cre ( $n=8$ ) and *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous floxed ( $n=10$ ) controls (Fig. 4a–c,

Supplementary Fig. 4; for single-cell PCR see ref. <sup>5</sup>). Basal discharge and peak responses to hypoxia were similar between the three groups (Fig. 4a–c, Supplementary Fig. 4) although a significant reduction in basal discharge was detected for the *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous knockouts when compared to *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous floxed mice by Student's *t* test ( $p < 0.05$ ) but not ANOVA. The  $PO_2$  required to reach a frequency of 5 Hz was reduced in the *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous floxed mice ( $73 \pm 5$  mmHg,  $p < 0.01$ ) and showed a similar trend in the *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous knockouts ( $80 \pm 5$  mmHg,  $p = 0.08$ ) compared to TH-Cre controls ( $96 \pm 4$  mmHg; Supplementary Fig. 4). There was, however, no difference in the  $PO_2$



**Fig. 3 Conditional deletion of *Lkb1* in carotid body type I cells attenuates basal and hypercapnia-evoked afferent discharge from the carotid body in vitro.** **a** shows (I) extracellular recordings of chemoafferent discharge versus time during normoxia/normocapnia and hypercapnia and (II) frequency-time histograms for carotid bodies from control (TH-Cre, black;  $n = 7$  different carotid bodies), homozygous *Lkb1* floxed (*Lkb1* hom Fx, blue;  $n = 6$  different carotid bodies) and conditional *Lkb1* homozygous knockout (*Lkb1* hom KO, red;  $n = 4$  different carotid bodies) mice (inset: single fibre discriminations). **b** shows mean  $\pm$  SEM for chemoafferent discharge versus  $PCO_2$ . **c** Dot plots show mean  $\pm$  SEM for  $CO_2$  sensitivity for TH-Cre (black), *Lkb1* hom Fx (blue) and *Lkb1* hom KO (red). \*\*= $p < 0.01$ .

required to reach a frequency of 5 Hz between *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous floxed mice and *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous knockouts. Exponential rate constants were consistent between the three groups (Supplementary Fig. 4). Moreover, carotid body responses to hypercapnia and  $CO_2$ -sensitivity remained unaltered in *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous knockouts ( $n = 9$ ) compared to TH-Cre ( $n = 7$ ) and *AMPK $\alpha$ 1 +  $\alpha$ 2* homozygous floxed mice ( $n = 9$ ; Fig. 4d–f, Supplementary Fig. 4).

Taken together, these findings suggest that LKB1 establishes, independent of AMPK, carotid body sensitivity to hypoxia and hypercapnia through a related mechanism, the set-point of which can be adjusted by changes in LKB1 expression. By contrast, within type I cells AMPK may support an inhibitory input on basal afferent discharge during normoxia.


**The HVR is attenuated in mice with LKB1 deficiency but remains unaffected following *Camkk2* deletion.** Under normoxia, there was no difference between controls and either *Lkb1*, *Camkk2*, or, as previously shown<sup>5</sup>, dual *AMPK $\alpha$ 1 +  $\alpha$ 2* knockouts with respect to breathing frequency, tidal volume, minute ventilation, blood gases, blood pH, or core body temperature (Supplementary Fig. 5 and Table 1). Moreover, the metabolic status of *Lkb1* floxed mice is normal<sup>23</sup>. Nevertheless, profound genotype-specific differences were observed with respect to the ventilatory responses during hypoxia, and to a lesser extent during hypercapnia (Supplementary Movies 1–4).

During exposures to poikilocapnic hypoxia, the peak of the initial “Augmenting Phase” of the HVR ( $\sim 30$  s) remained unaffected in *Lkb1* floxed mice (12%  $O_2$ ,  $n = 14$ ; 8%  $O_2$ ,  $n = 16$ ) that harbour  $\sim 90\%$  global reductions in LKB1 expression<sup>23</sup> when compared to TH-Cre ( $n = 25$ ). By contrast, the subsequent “Sustained Phase” (2–5 min) of the HVR was attenuated during severe poikilocapnic hypoxia (8%  $O_2$ ;  $p < 0.0001$  relative to TH-Cre;  $n = 37$ ) but not during moderate (12%  $O_2$ ;  $n = 25$ ; 8%  $O_2$ ,  $n = 37$ ) poikilocapnic hypoxia (Fig. 5a, b); i.e., these mice exhibited delayed hypoventilation during severe hypoxia.

The effect of conditional *Lkb1* deletion in catecholaminergic cells was more severe (Fig. 5a, b). The HVR was suppressed throughout 5 min exposures to either mild (Fig. 5b; 12%  $O_2$ ,  $n = 14$ ) or severe hypoxia (Fig. 5b; 8%  $O_2$ ,  $n = 15$ ), and in a manner related to the severity of hypoxia. In marked contrast to the outcomes for mice with hypomorphic expression of LKB1, complete *Lkb1* deletion markedly attenuated the peak change in minute ventilation of the initial “Augmenting Phase” of the HVR during mild and severe hypoxia (at  $\sim 30$  s;  $p < 0.0001$  compared to TH-Cre), which is primarily driven by carotid body afferent input responses<sup>1,31,32</sup>. Following subsequent ventilatory depression (Roll Off,  $\sim 100$  s) the HVR was attenuated during mild hypoxia ( $p < 0.0001$ , compared to TH-Cre), but this did not reach significance during severe hypoxia. However, the latter Sustained Phase of the HVR (2–5 min) was markedly attenuated during mild ( $p < 0.0001$ , compared to TH-Cre) and severe hypoxia ( $p < 0.01$ , compared to TH-Cre). Note that the 0.05%  $CO_2$  used here was probably insufficient to prevent respiratory alkalosis which may have impacted ventilatory reflexes during the latter phases of the sustained hypoxic stimulus<sup>33</sup>, in wild-type mice in particular. Therefore, we may have underestimated the degree to which *Lkb1* deletion inhibits the HVR.

By contrast to the effects of *Lkb1* deletion, global deletion of *Camkk2* ( $n = 10$ ) had no discernable effect on the HVR (Supplementary Fig. 6), ruling out a prominent role for CaMKK2 in facilitating the acute HVR alone or through AMPK activation<sup>19</sup>.

More detailed analysis in *Lkb1* floxed mice identified attenuation of increases in breathing frequency at all time points during the exposure to severe (8%  $O_2$ ,  $n = 22$ ) but not mild hypoxia (12%  $O_2$ ,  $n = 15$ ), including therein the Augmenting Phase ( $p < 0.05$  relative to TH-Cre), Roll Off ( $p < 0.0001$  relative to TH-Cre) and the Sustained Phase ( $p < 0.0001$  relative to TH-Cre). Increases in breathing frequency during hypoxia were yet more markedly attenuated by homozygous *Lkb1* deletion throughout exposures to both mild and severe hypoxia ( $p < 0.0001$  relative to TH-Cre; Fig. 6a), and in a manner proportional to the severity of hypoxia. By contrast, no attenuation of increases in tidal volume was observed for either *Lkb1* floxed mice or *Lkb1* knockouts during mild or severe hypoxia (Fig. 6b). In fact, during severe hypoxia *Lkb1* deletion in catecholaminergic cells, but not hypomorphic expression of LKB1, appeared to augment increases in tidal volume during



**Fig. 4** Conditional deletion of AMPK- $\alpha 1 + \alpha 2$  in carotid body type I cells has no effect on hypoxia-evoked or hypercapnia-evoked afferent discharge from the carotid body in vitro. **a** Shows (I) extracellular recordings of chemoafferent discharge versus time during normoxia and hypoxia and (II) frequency-time histograms (inset: single fibre discriminations) for carotid bodies from AMPK $\alpha 1 + \alpha 2$  homozygous floxed (AMPK $\alpha 1 + \alpha 2$  hom Fx, beige;  $n = 9$  different carotid bodies) and conditional homozygous AMPK $\alpha 1 + \alpha 2$  knockout mice (AMPK $\alpha 1 + \alpha 2$  hom KO, purple;  $n = 9$  different carotid bodies). **b** Means  $\pm$  SEM for frequency- $P_{O_2}$  response curves for AMPK $\alpha 1 + \alpha 2$  hom Fx and AMPK $\alpha 1 + \alpha 2$  hom KO. **c**, **d** Dot plots show mean  $\pm$  SEM for **c** basal single fibre discharge frequency and **d** peak single fibre discharge frequency during hypoxia for controls TH-Cre, black;  $n = 8$  different carotid bodies), AMPK $\alpha 1 + \alpha 2$  hom Fx and AMPK $\alpha 1 + \alpha 2$  hom KO. **e** as for **a** but in response to hypercapnia. **f** Means  $\pm$  SEM for frequency- $P_{CO_2}$  relationship. **g** Dot plot shows mean  $\pm$  SEM for CO<sub>2</sub> sensitivity.

Roll Off and the Sustained Phase ( $p < 0.01$  relative to TH-Cre), but not during the initial Augmenting Phase.


Conditional deletion of AMPK $\alpha 1 + \alpha 2$  in catecholaminergic cells also attenuated increases in breathing frequency, but not tidal volume, when these mice were exposed to mild hypoxia (12% O<sub>2</sub>; Fig. 6a, b;  $n = 30$ ) including therein the Augmenting Phase ( $p < 0.0001$  relative to TH-Cre), Roll Off ( $p < 0.0001$  for 12% O<sub>2</sub>;  $p < 0.001$  for 8% O<sub>2</sub>; relative to TH-Cre) and the Sustained Phase ( $p < 0.0001$  relative to TH-Cre). By contrast to the impact of *Lkb1* deletion, however, AMPK $\alpha 1 + \alpha 2$  deletion attenuated increases in tidal volume as well as increases in breathing frequency during severe hypoxia (8% O<sub>2</sub>;  $n = 26$ )<sup>5</sup>, including therein the Augmenting Phase ( $p < 0.05$  relative to TH-Cre for tidal volume and  $p < 0.0001$  for breathing frequency), Roll Off ( $p < 0.001$  relative to TH-Cre) and the Sustained Phase ( $p < 0.0001$  relative to TH-Cre).

Taken together these findings strongly suggest that LKB1 and AMPK facilitate the HVR and oppose respiratory depression during hypoxia. However, outcomes indicate that those catecholaminergic circuit mechanisms that mediate hypoxia-evoked increases in tidal volume are afforded greater protection from the impact of LKB1 and AMPK deficiency than those delivering increases in breathing frequency.

***Lkb1* deletion causes marked ventilatory instability, apnoea and Cheyne-Stokes-like breathing during hypoxia.** Unlike our

previously reported findings in mice with AMPK $\alpha 1 + \alpha 2$  deletion<sup>5</sup>, average measures (excluding apnoeas) for *Lkb1* knockouts indicated significant augmentation rather than the attenuation of increases in tidal volume during severe hypoxia, as mentioned above (Fig. 6b). Closer inspection revealed that attenuation of the HVR in *Lkb1* knockouts during exposure to severe hypoxia was associated with periods of Cheyne-Stokes-like breathing (CSB), where tidal volume exhibited marked sinusoidal variations with time (Fig. 7a, b; Supplementary Movie 2). CSB in *Lkb1* knockout mice was generally separated by periods of hypoventilation interspersed with frequent, prolonged apnoeas ( $\leq 4$  s). Unlike CSB, hypoventilation and apnoea were observed during mild and severe hypoxia. Increases in apnoea frequency ( $p < 0.05$  for 12% O<sub>2</sub> and  $p < 0.0001$  for 8% O<sub>2</sub>), apnoea duration ( $p < 0.0001$ ) and apnoea-duration index (frequency  $\times$  duration;  $p < 0.0001$ ) were all significantly greater than for controls (TH-Cre; Fig. 7c–e). As we have observed with respect to minute ventilation these measures also increased in a manner directly related to the severity of hypoxia. Moreover, CSB and increases in apnoea frequency and duration observed during severe hypoxia were completely reversed by





**Fig. 5 Mice hypomorphic for LKB1 exhibit an attenuated hypoxic ventilatory response measured by unrestrained plethysmography.** **a** Example records of minute ventilation versus time. **b** Dot plots of mean  $\pm$  SEM for % change in minute ventilation at the peak of the Augmenting Phase (AP, -30 s), after Roll Off (RO, -100 s) and during the plateau of the Sustained Phase (SP, -300 s) of the ventilatory response to 12% and 8% O<sub>2</sub> for TH-Cre (black; 12% O<sub>2</sub>,  $n = 25$  independent experiments; 8% O<sub>2</sub>,  $n = 37$  independent experiments), *Lkb1* homozygous floxed (*Lkb1* hom Fx, blue; 12% O<sub>2</sub>,  $n = 14$  independent experiments; 8% O<sub>2</sub>,  $n = 15$  independent experiments) and conditional *Lkb1* homozygous knockout mice (*Lkb1* hom KO, red;  $n = 22$  independent experiments; 8% O<sub>2</sub>,  $n = 30$  independent experiments). \*\*= $p < 0.01$ ; \*\*\*\*= $p < 0.0001$ .

hypercapnic hypoxia (Fig. 7aIII; Supplementary Movie 3), likely due to improved oxygen supply consequent to increases in ventilation (see below). Therefore, the appearance of CSB likely accounts for measured increases in tidal volume for *Lkb1* knockout mice relative to controls, despite the appearance of frequent prolonged apnoeas and lengthy intervening periods of pronounced hypoventilation, that are highlighted by Poincaré plots of inter-breath interval (BB<sub>n</sub>) versus subsequent inter-breath interval (BB<sub>n</sub> + 1; Supplementary Figs. 7, 8).

In this context, it is interesting to note that hypoxia-evoked CSB in *Lkb1* knockouts occurred irrespective of whether they were preceded by spontaneous or post-sigh apnoeas (Fig. 7b). Moreover frequent and prolonged spontaneous and post-sigh apnoeas were also observed in *AMPK- $\alpha$ 1 +  $\alpha$ 2* knockouts, where CSB is absent during 5 min (Supplementary Movie 4)<sup>5</sup> or even 10 min (Supplementary Fig. 9) exposures to severe hypoxia. Therefore, if sighs were triggered by hypoxia at a given threshold<sup>34</sup>, central hypoxia is likely no more severe for *Lkb1* when compared to *AMPK $\alpha$ 1 +  $\alpha$ 2* knockouts. CSB is thus most likely a consequence of LKB1 deficiency in type I cells and downstream catecholaminergic cardiorespiratory networks.

**Conditional *Lkb1* deletion slows the ventilatory response to hypercapnia and hypercapnic hypoxia.** The ventilatory response to hypercapnic hypoxia (8% O<sub>2</sub> + 5% CO<sub>2</sub>;  $n = 15$ ) in *Lkb1* knockouts was attenuated, but only during the rising phase (Fig. 8a;  $p < 0.01$  relative to TH-Cre,  $n = 17$ ). In short, *Lkb1* deletion slowed the rising phase of the response to this stimulus but did not affect the peak achieved. It is conceivable that the slow rise in this response may result from the residual attenuation of ventilatory responses to hypoxia that are not compensated for by increased central hypercapnic ventilatory drive. However, the rise in minute ventilation during exposure to hypercapnia alone (5% CO<sub>2</sub>;  $n = 20$ ) was also slower for *Lkb1* knockouts relative to controls ( $p < 0.05$  relative to TH-Cre,  $n = 20$ ), but thereafter achieved an equivalent magnitude (Fig. 8b) through increases in both respiratory frequency and tidal volume (Supplementary Fig. 10). By contrast, mice with *AMPK $\alpha$ 1 +  $\alpha$ 2* deletion exhibited no such delay in onset of hypercapnic ( $n = 23$ ) or hypoxic-hypercapnic ( $n = 22$ ) ventilatory responses<sup>5</sup> (Fig. 8a, b). The most


likely explanation for these findings, therefore, is the loss of carotid body chemoafferent input responses in *Lkb1* knockouts. This is in accordance with our aforementioned finding that hypoxia- and hypercapnia-evoked increases in afferent discharge were virtually abolished in carotid bodies from *Lkb1* knockouts and the generally held view that carotid body chemoafferent input responses drive the augmenting phase of the HVR<sup>31,35</sup>.

**The rank order of severity for attenuation of carotid body activation and attenuation of the HVR by LKB1 and AMPK is different.** Peak afferent discharge from the carotid body during hypoxia remained unaffected following dual *AMPK $\alpha$ 1 +  $\alpha$ 2* deletion<sup>5</sup>, while hypomorphic expression of LKB1 modestly attenuated increases afferent fibre discharge from the carotid body during hypoxia and *Lkb1* deletion virtually abolished carotid body afferent discharge during normoxia and hypoxia. By contrast, the Sustained Phase of the HVR during severe hypoxia was modestly attenuated by hypomorphic expression of *Lkb1*, markedly attenuated by homozygous *Lkb1* deletion but most severely attenuated by *AMPK $\alpha$ 1 +  $\alpha$ 2* deletion. In short, the rank order by degree of inhibition of peak carotid body afferent fibre discharge during hypoxia on the one hand and the sustained phase of the HVR on the other is different (Supplementary Fig. 11).

## Discussion

The present study identifies an essential role for LKB1 in establishing carotid body function and chemosensitivity, where the level of LKB1 expression determines a set-point about which carotid body afferent discharge is modulated by hypoxia and hypercapnia. This strongly suggests that the metabolic signalling pathway(s) that mediates the response of carotid body type I cells to hypoxia cannot be attenuated without affecting CO<sub>2</sub> sensitivity. Moreover, we have uncovered a divergence in dependency on LKB1 and AMPK between the carotid body on the one hand and the HVR on the other (Fig. 9).

Deletion of LKB1, but not AMPK, in type I cells attenuated basal carotid body afferent discharge during normoxia and virtually abolished carotid body afferent input responses during hypoxia and hypercapnia, the latter of which was not thought to be determined by changes in mitochondrial metabolism<sup>26–29</sup>.




**Fig. 6 Conditional deletion of *Lkb1* and AMPK in tyrosine hydroxylase expressing cells attenuates increases in breathing frequency during hypoxia but only *Lkb1* deletion augments increases in tidal volume during severe hypoxia.** Dot plots of mean  $\pm$  SEM for changes in **a** breathing frequency and **b** tidal volume at the peak of the Augmenting Phase ( $\sim$ 30 s), at  $\sim$ 100 s following Roll Off and during the plateau of the Sustained Phase ( $\sim$ 300 s) of the ventilatory response to mild (12% O<sub>2</sub>) and severe (8% O<sub>2</sub>) hypoxia for TH-Cre (black; 12% O<sub>2</sub>,  $n = 25$  independent experiments; 8% O<sub>2</sub>,  $n = 37$  independent experiments), *Lkb1* homozygous floxed (*Lkb1* hom Fx, blue; 12% O<sub>2</sub>,  $n = 14$  independent experiments; 8% O<sub>2</sub>,  $n = 15$  independent experiments) that are  $\sim$ 90% hypomorphic for LKB1 and conditional *Lkb1* homozygous knockout mice (*Lkb1* hom KO, red; 12% O<sub>2</sub>,  $n = 22$  independent experiments; 8% O<sub>2</sub>,  $n = 30$  independent experiments). These data are also compared with outcomes for *AMPKα1 + α2* homozygous floxed mice (*AMPKα1 + α2* hom Fx, beige, 12% O<sub>2</sub>,  $n = 30$  independent experiments; 8% O<sub>2</sub>,  $n = 13$  independent experiments) and conditional *AMPKα1 + α2* homozygous knockout mice (*AMPKα1 + α2* hom KO, purple, 12% O<sub>2</sub>,  $n = 30$  independent experiments; 8% O<sub>2</sub>,  $n = 26$  independent experiments). \*= $p < 0.05$ , \*\*= $p < 0.01$ , \*\*\*= $p < 0.0001$  compared to TH-Cre.

Carotid bodies of mice that are  $\sim$ 90% hypomorphic for LKB1 expression in all cells (homozygous *Lkb1* floxed<sup>23</sup>) also exhibited significantly attenuated ( $\sim$ 50%) peak carotid body afferent discharge during hypoxia. Accordingly, homozygous *Lkb1* deletion abolished hypoxia-evoked cytoplasmic calcium transients in type I cells. Paradoxically, however, in type I cells from mice that were  $\sim$ 90% hypomorphic for LKB1 expression, hypoxia-evoked calcium transients were not only retained but augmented relative to controls. This suggests that the level of LKB1 expression determines a set-point about which type I cells are activated by hypoxia and hypercapnia, and that membrane depolarisation and exocytotic transmitter release are differentially sensitive to this.

It has been proposed that afferent discharge during hypoxia could, at least in part, be initiated by falls in type I cell cytoplasmic ATP<sup>36</sup> (although other mechanisms have also been considered<sup>37</sup>), which could trigger membrane depolarisation<sup>36</sup> and consequent exocytotic release of vesicular ATP to induce increases in afferent discharge<sup>38,39</sup>. It is intriguing to note, therefore, that previous studies on the effects of *Lkb1* deletion have identified changes in mitochondrial activities and consequent reductions in ATP levels and increases in AMP:ATP and ADP:ATP ratios in a variety of cell types, including skeletal muscle<sup>23</sup>, cardiac muscle<sup>24,40</sup>, pancreatic beta cells<sup>41,42</sup>, regulatory T Cells<sup>43</sup> and MIN6 cells<sup>41</sup>. More importantly still, it has been

demonstrated that ATP levels are lower in cardiac muscle from hypomorphic *Lkb1* floxed mice under normoxia, lower still in hearts from mice with cardiac-specific *Lkb1* deletion and that in each case ATP levels decline further during ischaemia<sup>24</sup>. Thus, LKB1 may maintain in an expression-dependent manner the capacity for ATP synthesis within most cells, including therein carotid body type I cells where ATP deficiency might ultimately impact on the capacity for uptake of ATP by synaptic vesicles and/or exocytotic release of ATP. This view gains indirect support from our finding that *Lkb1* deletion, but not hypomorphic expression of LKB1, showed signs of reducing basal afferent discharge during normoxia, while peak afferent discharge was mildly attenuated by hypomorphic expression of LKB1 ( $\sim$ 50%) and virtually abolished by *Lkb1* deletion. Further indirect support is provided by a previous study on rat carotid bodies, which showed that exocytotic release of adenosine represents the principal transmitter contributing to carotid body afferent discharge during mild hypoxia, while ATP acts as the principal transmitter driving afferent discharge during severe hypoxia (i.e., peak discharge frequency)<sup>44</sup>. Although counter-intuitive, a lowering of ATP levels could also explain why hypoxia-evoked calcium transients were augmented in carotid body type I cells with hypomorphic expression of LKB1 yet blocked by homozygous *Lkb1* deletion, if mid-range reductions in basal ATP levels confer




**Fig. 7 Conditional deletion of *Lkb1* in tyrosine hydroxylase expressing cells precipitates hypoventilation, apnoea and Cheyne-Stokes-like breathing during severe hypoxia.** **a** Example records of ventilatory activity from TH-Cre and conditional *Lkb1* homozygous knockout mice (*Lkb1* hom KO) during (I) normoxia (21% O<sub>2</sub>), (II) hypoxia (8% O<sub>2</sub>) and (III) hypoxia with hypercapnia (8% O<sub>2</sub> + 5% CO<sub>2</sub>), that were obtained using whole body plethysmography. **b** (I–II), Typical ventilatory records for TH-Cre and conditional *Lkb1* hom KO mice on an expanded time scale at the indicated time points during exposures to severe hypoxia (8% O<sub>2</sub>). Dot plots show mean ± SEM for **c** apnoeic frequency, **d** apnoea duration and **e** apnoea-duration index (frequency × duration) for TH-Cre (black; 12% O<sub>2</sub>, *n* = 19 independent experiments; 8% O<sub>2</sub>, *n* = 24 independent experiments) and conditional *Lkb1* hom KO mice (red; 12% O<sub>2</sub>, *n* = 17 independent experiments; 8% O<sub>2</sub>, *n* = 29 independent experiments) during exposures to 12% O<sub>2</sub>, 8% O<sub>2</sub> and 8% O<sub>2</sub> + 5% CO<sub>2</sub>. \*=*p* < 0.05, \*\*=*p* < 0.01, \*\*\*\*=*p* < 0.0001.


increased sensitivity of TASK1/3 channels to inhibition by hypoxia as previously proposed by others<sup>36</sup>, without greatly compromising the capacity for exocytotic ATP release. Further reductions in ATP availability upon homozygous *Lkb1* deletion could then ultimately render these ATP-sensitive TASK1/3 channels inactive, abolish hypoxia-response coupling in type I cells<sup>16,36,45</sup> and greatly reduce vesicular uptake and exocytotic ATP release<sup>38,39</sup>. This would also impact on type I cell activation by hypercapnia, due to the fact that this too is in great part mediated by inhibition of TASK1/3 channels through acidosis and consequent induction of exocytotic release of ATP, albeit in a manner independent of mitochondrial oxidative phosphorylation<sup>30</sup>. Indirect support for this proposal may be taken from the previous finding of others that inhibition of mitochondrial oxidative phosphorylation (oligomycin and antimycin A) in cat carotid bodies in-situ blocked responses to hypoxia and enhanced responses to hypercapnia in vivo<sup>30</sup>. If LKB1 deficiency did not reduce ATP availability, then one would expect similarly augmented changes in afferent discharge in response to hypercapnia rather than the decreases reported here. It is also notable that *Lkb1* deletion in pancreatic beta cells is

associated with lower glucose-induced ATP accumulation, enhanced membrane excitability and increased glucose-stimulated insulin release<sup>41,42</sup>. That said it is possible that LKB1 deficiency may increase or reduce other metabolic intermediates that might also impact type I cell responses to hypercapnia and thus O<sub>2</sub>:CO<sub>2</sub> stimulus interaction<sup>27,46</sup>. Either way, the precise AMPK-independent mechanism(s) by which LKB1 may “rewire cell metabolism” remains to be determined. However, it is intriguing to note that LKB1 can coordinate glucose homeostasis<sup>41,47,48</sup> and mitochondrial function through either a direct action<sup>41,49,50</sup>, or indirectly through constitutive phosphorylation of one or more of the eleven AMPK-related kinases it regulates<sup>13,51,52</sup>.

In line with the above, the HVR was attenuated in hypomorphic *Lkb1* floxed and homozygous *Lkb1* knockout mice in a manner related to the degree of LKB1 deficiency. By contrast, the HVR remained unaffected in global *Camkk2* knockouts. In short, LKB1 and AMPK signalling pathways are critical to the maintenance of breathing and oxygen supply during hypoxia<sup>53</sup>, and act in concert to oppose ventilatory depression, hypoventilation and apnoea<sup>5</sup>.



**Fig. 8 Conditional deletion of *Lkb1* in tyrosine hydroxylase expressing cells markedly slows the hypercapnic ventilatory response.** Dot plots show mean  $\pm$  SEM for increases in minute ventilation at ~30 s, 100 s and 300 s during exposures to **a** hypercapnic hypoxia (5% CO<sub>2</sub> + 8%O<sub>2</sub>) and **b** hypercapnia (5% CO<sub>2</sub>) for TH-Cre (black; 8% O<sub>2</sub> + 5% CO<sub>2</sub>, n = 17 independent experiments; 5% CO<sub>2</sub>, n = 20 independent experiments), conditional *Lkb1* homozygous knockout mice (*Lkb1* hom KO, red; 8% O<sub>2</sub> + 5% CO<sub>2</sub>, n = 15 independent experiments; 5% CO<sub>2</sub>, n = 20 independent experiments), *AMPKα1* + *α2* homozygous floxed mice (*AMPKα1* + *α2* hom Fx, beige; O<sub>2</sub> + 5% CO<sub>2</sub>, n = 20 independent experiments; 5% CO<sub>2</sub>, n = 20 independent experiments) and *AMPKα1* + *α2* homozygous knockout mice (*AMPKα1* + *α2* hom KO, purple, O<sub>2</sub> + 5% CO<sub>2</sub>, n = 22 independent experiments; 5% CO<sub>2</sub>, n = 23 independent experiments). \* = *p* < 0.05, \*\* = *p* < 0.01.



**Fig. 9 Graphical abstract showing the divergent pathways by which LKB1 and AMPK may coordinate the hypoxic ventilatory response.** *LKB1* liver kinase B1, *AMPK* AMP-activated protein kinase, *ARK* AMPK-related kinase, *NTS* nucleus tractus solitarius, *VLM* ventrolateral medulla.

We previously reported that dual *AMPKα1* + *α2* deletion in catecholaminergic cells blocked the HVR, with no discernable effect on carotid body afferent input responses to hypoxia<sup>5</sup>. The data presented here confirm this finding and show that carotid body CO<sub>2</sub> sensitivity remained unaltered following *AMPKα1* +

*α2* deletion. Therefore, our present findings support the idea that severe hypoventilation and apnoea observed during hypoxia in *AMPKα1* + *α2* knockout mice is due to dysfunction of central respiratory networks rather than any depletion of carotid body activity.

It is evident that *Lkb1* deletion in catecholaminergic neurons attenuated all phases of the HVR during mild (12% O<sub>2</sub>) and severe (8% O<sub>2</sub>) hypoxia, to a greater degree than with hypomorphic expression of LKB1 but less so than previously observed during severe hypoxia following *AMPKα1 + α2* deletion, even though carotid body afferent input responses were retained in *AMPKα1 + α2* knockouts<sup>5</sup>. In this respect, it is interesting to note that deficits in minute ventilation were evident for *Lkb1* floxed mice during the late Sustained Phase but not the Augmenting Phase of the HVR during severe hypoxia. This is consistent with the effect of *AMPKα1 + α2* deletion during mild hypoxia. Outcomes for *Lkb1* floxed mice and *AMPKα1 + α2* knockouts, therefore, add further weight to our proposal that they exert an inhibitory effect downstream of chemoafferent input responses, if one accepts the view that increases in carotid body afferent discharge drive the Augmenting Phase of the HVR<sup>31,35</sup> while direct modulation by hypoxia of brainstem respiratory networks aids maintenance of the HVR in the longer term<sup>1,5,32,35,54,55</sup>. Further support for this proposal is provided by the rank order of severity of hypoxic ventilatory and carotid body dysfunction, respectively. During severe hypoxia the HVR is inversely related to the degree of LKB1 deficiency but was most markedly inhibited following *AMPKα1 + α2* deletion<sup>5</sup>, despite the fact that carotid body afferent discharge during hypoxia (and hypercapnia) was attenuated in a manner directly related to the degree of *Lkb1* deletion but remained unaffected following *AMPKα1 + α2* deletion.

When taken together, these data strongly suggest that LKB1 determines, independent of AMPK, a set-point about which carotid body afferent input responses are delivered during hypoxia and provide further strong support for our previous proposal that LKB1-AMPK signalling pathways facilitate the HVR at the brainstem. In this way, LKB1 and AMPK may exert independent influences on peripheral<sup>27,46</sup> and central<sup>31,35,55,56</sup> stimulus interactions. Accordingly, the rising phase of the hypercapnic and hypoxic-hypercapnic ventilatory responses was slowed in *Lkb1* knockouts, while by contrast the peak of the Sustained Phase of both responses remained unaltered despite a marked attenuation of afferent input responses to hypercapnia.

This is a major point because homozygous *Lkb1* deletion led to marked reductions in breathing frequency (excluding apnoeas) that were coupled with erratic “augmentation” of tidal volume responses during severe hypoxia, consequent to induction of periodic Cheyne-Stokes-like breathing patterns. Cheyne-Stokes-like breathing patterns were never observed in mice with either ~90% global hypomorphic LKB1 expression or *AMPKα1 + α2* deletion in catecholaminergic cells. A critical distinguishing factor in this respect may therefore be the block by *Lkb1* deletion of not only carotid body afferent input responses to hypoxia and hypercapnia, but also concomitant attenuation of downstream hypoxia-responsive circuit mechanisms. This suggests that Cheyne-Stokes breathing may occur consequent to energy crises in peripheral and central catecholaminergic respiratory control networks. That said, others have proposed that Cheyne-Stokes breathing is triggered by hyperactivity of carotid bodies and thus augmented afferent input responses when associated with heart failure<sup>57</sup>. One possible explanation for these contradictory observations could be that enhanced carotid body afferent input responses after heart failure occur consequent to the central metabolic crisis that results in abject failure of both central integration of afferent inputs and efferent ventilatory output. In other words, increases in controller gain within the central respiratory networks could trigger Cheyne-Stokes breathing by enhancing the sensitivity to, and thus the degree of activation of central CO<sub>2</sub>-sensing neurons during hypercapnia<sup>31</sup> consequent to hypoventilation and apnoea during hypoxia. Consistent with this

view, others have proposed that Cheyne-Stokes breathing may be caused by enhanced hypercapnic ventilatory responses driven by instability within respiratory networks consequent to augmented chemoreflex gain, prolonged feedback delay<sup>58</sup> and/or enhanced central controller gain<sup>59</sup>.

The more extreme patterns of non-rhythmic (ataxic) ventilation observed for *AMPKα1 + α2* knockouts<sup>5</sup> may thus be avoided. While unlikely it is also conceivable that retention by *Lkb1* knockouts of greater capacity for rhythmic ventilation during hypoxia could be conferred by residual allosteric AMPK activation by AMP in central hypoxia-responsive respiratory networks<sup>60</sup>, where falls in cellular ATP supply would be associated with ADP accumulation and consequent increases in the AMP:ATP ratio via the adenylate kinase reaction. This could conceivably maintain oscillating central respiratory drive in a manner triggered periodically once a given severity of central hypoxia is breached. That said, central hypoxia is likely no more severe for *Lkb1* when compared to *AMPKα1 + α2* knockouts because: (1) hypoxia-evoked sighs<sup>34,61</sup> were observed in *Lkb1* and *AMPKα1 + α2* knockouts; (2) apnoeas were shorter and less frequent for *Lkb1* knockouts when compared to *AMPKα1 + α2* knockouts;<sup>5</sup> (3) Cheyne-Stokes-like breathing between apnoeas would periodically raise oxygen supply in *Lkb1* knockouts.

In conclusion, the present study reveals that the level of LKB1 expression is essential for establishing carotid body function and for initiating the HVR. In this respect, LKB1 and AMPK provide for hierarchical control of the hypoxia-responsive respiratory network (Fig. 9). Firstly, the level of LKB1 expression determines, independent of AMPK, a set-point about which carotid body afferent input responses are evoked during hypoxia and hypercapnia, rather than contributing to oxygen-sensing per se. Thereafter LKB1-AMPK signalling pathways likely govern coincidence detection and signal integration within a hypoxia-responsive circuit downstream of the carotid bodies, that encompasses, at the very least, the brainstem nucleus of the solitary tract<sup>5</sup>. Afferent input responses and brainstem hypoxia could thereby determine, each in part, the set-point about which AMPK and thus brainstem respiratory networks are activated during hypoxia. Subsequently, AMPK-dependent modulation of cellular metabolism<sup>60</sup>, ion channels<sup>62,63</sup> and thereby neuronal activities<sup>64,65</sup> may facilitate afferent inputs and thus efferent outputs leading to increases in ventilatory drive during hypoxia. Consequently, LKB1 and/or AMPK deficiency may contribute to central sleep apnoea associated with metabolic syndrome-related disorders<sup>66</sup>, ascent to altitude<sup>67</sup> and apnoea of prematurity<sup>68</sup>. By contrast, Cheyne-Stokes breathing and central sleep apnoea<sup>58</sup> associated with heart failure<sup>57</sup> may be conferred by LKB1 deficiency and/or metabolic crises across peripheral and central hypoxia-responsive respiratory networks. Further studies are therefore warranted to elucidate the downstream AMPK-independent targets by which LKB1 establishes carotid body function.

## Methods

Experiments were approved by local ethical review committees and the University Director of Veterinary Services at the University of Edinburgh, and the UK Home Office (Science). All procedures were covered by a UK Home Office Project Licence (PBA4DC9D). All genetically modified mice tested here were bred on a C57 Black 6 (C57/BL6) background. Furthermore, all studies complied with the regulations of the United Kingdom Animals (Scientific Procedures) Act of 1986.

**Breeding of mice, genotyping and single-cell PCR.** Standard approaches were used for breeding mice and brother/sister mating was avoided. All mice studied were between 3 and 12 months of age.

Because global deletion of the gene encoding LKB1 (*Stk11*, *Lkb1*) or dual deletion of the genes encoding AMPKα1 (*Prkaa1*) and AMPKα2 (*Prkaa2*) is embryonic lethal, we employed knockdown and/or conditional deletion strategies. For *Lkb1* deletion, we used floxed mice in which exons 5–7 of this gene had been

replaced by a cDNA cassette encoding equivalent exon sequences where exon 4 and the cDNA cassette were flanked by loxP sequences, which in their own right deliver ~90% global knockdown of LKB1 expression<sup>23</sup>. For *AMPKα1* +  $\alpha2$  deletion critical exons of the *AMPKα1* and *AMPKα2* genes were flanked by loxP sequences<sup>69</sup>. Each floxed mouse line was crossed, as previously described<sup>5</sup>, with mice expressing Cre recombinase under the control of the TH promoter (Th-IRES-Cre; EM:00254), providing for gene deletion in all catecholaminergic cells inclusive of those cells that constitute the hypoxia-responsive respiratory network from carotid body<sup>70</sup> to brainstem<sup>71</sup>. Transient developmental expression of TH does occur in disparate cell types that do not express TH in the adult<sup>72</sup>, such as dorsal root ganglion cells and pancreatic islets, but these do not contribute to the acute HVR. We previously confirmed restriction of Cre expression to TH-positive cells in the adult mouse by viral transfection of a Cre-inducible vector carrying a reporter gene<sup>5</sup>. Therefore, our approach overcomes embryonic lethality and allows, unforeseen ectopic Cre expression aside, for greater discrimination of circuit mechanisms than would be provided for by global knockouts. The role of CaMKK2 in the HVR was determined by assessing mice with global deletion of the corresponding gene (*Camkk2*)<sup>22</sup>.

Male *Lkb1*<sup>flx/flx</sup> mice are infertile. To overcome this issue female *Lkb1*<sup>flx/flx</sup> mice were crossed with heterozygous male TH-Cre<sup>+/-</sup> mice. Heterozygous males of the *Lkb1*<sup>flx/wt</sup> Cre<sup>+/-</sup> genotype were then backcrossed with female homozygous *Lkb1*<sup>flx/flx</sup> Cre<sup>+/-</sup> mice to obtain the required *Lkb1*<sup>flx/flx</sup> Cre<sup>+/-</sup> mice to study. Wildtype or floxed *Lkb1* alleles were detected using two primers, p200, 5'-CCAGCCTTCTGACTCTCAGG-3' and p201, 5'-GTAGGTATTCCAGGCCG TCA-3'. For the detection of Cre recombinase we employed: TH3, 5'-CTTTC CTTCCTTTATTGAGAT-3', TH5, 5'-CACCTGACCCAAGCACT-3' and Cre-UD, 5'-GATACCTGGCTGGTCTCG-3'. As homozygous *Lkb1* floxed mice are hypomorphic, exhibiting ~90% lower LKB1 expression than *Lkb1* wildtype littermates<sup>23</sup>, we used as controls mice that express Cre via the TH promoter (TH-Cre).

For deletion of the gene that encodes CaMKK2 (*CamKK2*) wildtype alleles were detected using two primers, KKBeta1, 5'CAGCACTCAGCTCCAATCAA3' and KKBeta2, 5'GCCACCTATTGCC TTGTTTG3'.

Lastly, we used two primers for each AMPK catalytic subunit:  $\alpha1$ -forward: 5' TATTGCTGCCATTAGGCTAC 3',  $\alpha1$ -reverse: 5' GACCTGACAGAATAGG ATATGCCAACCTC 3';  $\alpha2$ -forward 5' GCTTAGCACGTTACCCTGGATGG 3',  $\alpha2$ -reverse: 5' GTTATCAGCCCAACTAATTACAC 3'.

We detected the presence of wild-type or floxed alleles and Cre recombinase by PCR. The PCR protocol used for all genotype primers was: 92 °C for 5 min, 92 °C for 45 s, 56 °C for 45 s, 72 °C for 60 s and 72 °C for 7 min for 35 cycles and then 4 °C as the holding temperature. 15  $\mu$ l samples were run on 2% agarose gels with 10  $\mu$ l SYBR®Safe DNA Gel Stain (Invitrogen) in TBE buffer against a 100 bp DNA ladder (GeneRuler™, Fermentas) using a Model 200/2.0 Power Supply (Bio-Rad). Gels were imaged using a Genius Bio Imaging System and GeneSnap software (Syngene).

**Type I cell isolation.** Carotid bodies were incubated at 37 °C for 25–30 min in isolation medium consisting of: 0.125 mg/ml Trypsin (Sigma), 2.5 mg/ml collagenase Type 1 (Worthington) made up in low Ca<sup>2+</sup>/low Mg<sup>2+</sup> HBSS. During this incubation, the carotid bodies were separated from the associated patch of artery. The carotid bodies were then transferred to low Ca<sup>2+</sup>/low Mg<sup>2+</sup> HBSS containing trypsin inhibitor (0.5 mg/ml) for 5 min at room temperature, and then to 2 ml of pre-equilibrated (95% air, 5% CO<sub>2</sub>, 37 °C) growth medium (F-12 Ham nutrient mix, 10% fetal bovine serum, 1% penicillin/streptomycin). The medium containing the carotid bodies was centrifuged and the pellet was re-suspended in 100  $\mu$ l of growth medium. Carotid bodies were then disrupted by triturating using fire-polished Pasteur pipettes, and type I cells were used within 4 hr.

**Confocal and Immunofluorescence imaging.** To aid confirmation that *Lkb1* deletion had been induced in carotid body type I cells, mice with TH-Cre driven gene deletion were crossed with mice engineered for Cre-dependent expression of tdTomato (excitation 555 nm, emission 582 nm) from the Rosa26 locus. These mice were deeply anaesthetised using 2 g/kg Pentobarbital Sodium (Merial) and carotid bifurcations containing the carotid body tissue dissected out. Bifurcations were briefly washed in ice-cold saline, fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.4), post-fixed and stored in 30% sucrose in 0.1 M PB at 4 °C. 5  $\mu$ m sections of the bifurcations were cut using a cryostat, collected on glass slides and air-dried before being rinsed in 0.1 M phosphate-buffered saline (PBS) and glass coverslipped. Confocal z sections were acquired using a Nikon AIR + confocal system via a Nikon Eclipse Ti inverted microscope with a Nikon Apo 63 Å- $\lambda$ S DIC N2, 1.25 n.a. oil immersion objective (Nikon Instruments Europe BV, Netherlands). Image processing was carried out using Imaris (Bitplane, Oxford Instruments, UK) and ImageJ (Rasband WS. ImageJ, U.S. National Institutes of Health, Bethesda, MD, USA, [imagej.nih.gov/ij/](http://imagej.nih.gov/ij/), 1997–2012).

Additionally, carotid body type I cells were isolated and processed for immunocytochemistry. Briefly, slides were washed in 0.1 M PBS, incubated overnight in anti-TH (mouse; 1:1000 dilution; Merck Millipore MAB318) primary antibodies diluted in 2% v/v normal serum in 0.1 M PB-T (0.3% v/v Triton™ X-100; Sigma), rinsed 3 $\times$  for 5 min in 0.1 M PBS and incubated in fluorescent secondary antibodies (Alexa Fluor® 488; goat anti-mouse; 1:750 dilution; Thermo

Fisher A-11034) for 2 hr at room temperature. Slides were washed again, followed by incubation with DAPI (1  $\mu$ g/ml) for 5 min at room temperature, 3  $\times$  5 min washed with 0.1 M PBS and glass coverslipped.

**Single-cell end-point PCR.** For single-cell amplification, GoTaq DNA Polymerase (Promega) was added to 2–5  $\mu$ l of cDNA obtained from each single carotid body type I cell from wildtype and transgenic mice as well as the wildtype adrenomedullary chromaffin cells. To ensure the validity that the collected cells were indeed carotid body type I cells and adrenomedullary chromaffin cells, primers obtained from Qiagen were used to detect the expression of TH (QuantiTect Primer Assay, QT00101962) with an expected band length of 92 bp. The only cells considered for the expression studies were those that positively expressed TH and where the negative controls were clean. Primers designed by Qiagen for LKB1 were not used as they detect areas of the genes that are not within the floxed loxP sites, which may result in false positives appearing if mRNA transcript is still produced regardless of whether the targeted domain has been excised. Accordingly, primers were designed by using Primer-BLAST (NCBI) to detect a region that is known to be excised: FWD: 5'GCTCATGGGTA CTTCGCCAGC 3'; REV:5'AGCAGGTTGCC CGGCTTGATG 3'. 15  $\mu$ l samples along with a 100 bp DNA Ladder (GeneRuler™, Fermentas) were run on a 2% agarose gel made with SYBR®Safe DNA gel stain (Invitrogen). Gels were then imaged using a Genius Bio Imaging System and GeneSnap Software (Syngene).

**Quantitative RT-PCR.** RNA was extracted, quantified and reverse transcribed as described above. For qPCR analysis, 2.5  $\mu$ l of cDNA in RNase-free water was made up to 25  $\mu$ l with FastStart Universal SYBR Green Master (ROX, 12.5  $\mu$ l, Roche), Ultra Pure Water (8  $\mu$ l, SIGMA) and forward and reverse primers for LKB1. The sample was then centrifuged and 25  $\mu$ l added to a MicroAmp™ Fast Optical 96-Well Reaction Plate (Greiner bio-one), the reaction plate sealed with an optical adhesive cover (Applied Biosystems) and the plate centrifuged. The reaction was then run on a sequence detection system (Applied Biosystems) using AmpliTaq Fast DNA Polymerase, with a 2 min initial step at 50 °C, followed by a 10 min step at 95 °C, then a 15 s step at 95 °C which was repeated 40 times. Then a dissociation stage with a 15 s step at 95 °C followed by a 20 s at 60 °C and a 15 s step at 95 °C. Negative controls included control cell aspirants for which no reverse transcriptase was added, and aspiration of extracellular medium and PCR controls. None of the controls produced any detectable amplicon, ruling out genomic or other contamination.

**Calcium imaging.** Type I cells were incubated in the standard perfusate with 4  $\mu$ M Fura-2 AM (Molecular Probes) at room temperature, washed and then placed in a temperature-regulated perfusion chamber on a Nikon Diaphot 300 inverted phase-contrast microscope. Cells were perfused with a solution consisting of (mM): NaCl (117), KCl (4.5), MgCl<sub>2</sub> (1), CaCl<sub>2</sub> (2.5), NaHCO<sub>3</sub> (23), Glucose (10), pH adjusted to 7.4 using 5% CO<sub>2</sub>. For normoxia perfusate was bubbled with 5% CO<sub>2</sub> 95% air (~150 mmHg). For hypoxia perfusate was bubbled with 5% CO<sub>2</sub>, 95 % nitrogen (~20 mmHg).

**Extracellular recordings of carotid sinus nerve activity.** Single fibre chemoafferent activity was amplified, filtered and recorded using a 1401 interface running Spike 2 software (Cambridge Electronic Design). Single- or few-fibre chemoafferent recordings were made from carotid bifurcations held in a small volume tissue bath (36–37 °C), and superfused with gassed (95% O<sub>2</sub> and 5% CO<sub>2</sub>), bicarbonate-buffered saline solution (composition (mM): 125 NaCl, 3 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 5 Na<sub>2</sub>SO<sub>4</sub>, 1.3 MgSO<sub>4</sub>, 24 NaHCO<sub>3</sub>, 2.4 CaCl<sub>2</sub>, pH 7.4). A standard O<sub>2</sub> electrode (ISO2; World Precision Instruments) was placed in the superfusate system at the point of entry to the recording chamber in order to continuously record the superfusate PO<sub>2</sub>. Flow metres with high precision valves (Cole Palmer Instruments) were used to equilibrate the superfusate with the desired gas mixture. Basal single fibre activity was monitored at a superfusate PO<sub>2</sub> of 200 mmHg and a PCO<sub>2</sub> of 40 mmHg. This PO<sub>2</sub> is slightly lower than that previously used for the rat carotid body<sup>73</sup> to take in account the smaller size of this organ in the mouse (and thus a smaller diffusion distance). At this superfusate PO<sub>2</sub>, the basal frequency in TH-Cre single/few fibres was consistent with that reported in vivo in other rodents<sup>74</sup> and so we interpret this PO<sub>2</sub> to have not been excessively hyperoxic.

To induce responses to hypoxia, the superfusate PO<sub>2</sub> was slowly reduced to a minimum of 40 mmHg or was reversed prior to this when the chemoafferent response had stabilised or had begun to diminish. The single fibre chemoafferent discharge frequency was plotted against the superfusate PO<sub>2</sub> over a desired range of superfusate PO<sub>2</sub> values. To produce the hypoxic response curves, the data points were fitted to an exponential decay curve with offset, as shown below:

$$y = a + be^{-cx}$$

For the above equation, y is the single fibre discharge frequency in Hz, x is the superfusate PO<sub>2</sub> in mmHg, a is the discharge frequency as the PO<sub>2</sub> tends to infinity (offset), b is the discharge frequency when the PO<sub>2</sub> is 0 mmHg (minus the offset) and c is the exponential rate constant. Comparison of the exponential rate constants allowed for determination of any alteration in the rate of increase in chemoafferent frequency per mmHg reduction in the superfusate PO<sub>2</sub>, upon

hypoxic response initiation. Furthermore, for any given discharge frequency, the corresponding  $PO_2$  could be calculated using the inverse function of the exponential decay curve, as shown below:

$$y = (\ln((x - a)/b))/ - c$$

$y$  is the  $PO_2$  in mmHg,  $x$  is the single fibre discharge frequency in Hz and  $a, b$  and  $c$  are constants as above. Specifically, superfusate  $PO_2$  levels were compared when the single fibre chemoafferent discharge frequency was at 5 Hz. This was chosen as it lies on the exponential region of the hypoxic response curve but is not of a magnitude at which the discharge is likely to have begun to diminish. This method was used to define any  $PO_2$  shift in the hypoxic response curve thereby providing information on a potential change in the  $PO_2$  threshold required for hypoxic response initiation. Plots of firing frequency versus superfusate  $PO_2$  were fitted by non-linear regression (GraphPad Prism 6).

Chemoafferent responses to hypercapnia were induced by raising the superfusate  $PCO_2$  from ~40 mmHg (pH 7.4) to 80 mmHg (pH 7.15) at a constant  $PO_2$  (200 mmHg), as has been previously reported for the intact in vitro CB preparation<sup>75</sup>.

**Plethysmography.** For plethysmography mice were 6–12 months of age. Both males and females were studied. We used unrestrained whole-body plethysmography, incorporating a Halcyon™ low noise pneumatochograph coupled to FinePointe acquisition and analysis software with a sampling frequency of 1 kHz (Buxco Research Systems, UK). All quoted values for the HVR were derived from apnoea-free periods of ventilation. All measures reported are averages of  $n$  repeats from multiple mice (C57/BL6, 5 mice; TH-Cre, 5 mice; *Lkb1* floxed, 4 mice; *Lkb1* knockout, 4 mice; CaMKK2 knockouts, 7 mice; AMPK- $\alpha$ 1/ $\alpha$ 2 floxed, 5 mice; AMPK- $\alpha$ 1/ $\alpha$ 2 floxed, 5 mice). Any unreliable and erratic respiratory waveforms recorded during gross un-ventilatory related body movements, i.e., sniffing and grooming, were avoided for measurements. Additionally, a rejection algorithm that was built into the plethysmography system (Buxco Electronics Inc.) identified periods of motion-induced-artefacts for omission. The patented Halcyon™ low noise pneumatochograph (Buxco Electronics Inc.) reduces disturbances caused by air currents from outside the chambers (i.e., fans, closing doors, air conditioners, etc.), which can disrupt or overwhelm the ventilatory airflows within the chamber.

Mice were trained by repeated bi-weekly placement in the plethysmography chamber under normoxia and without experimental interventions, so that they became accustomed to the environment. During experimental work mice were placed in a freshly cleaned plethysmography chamber (to remove scent of previous mice) for a 10–20 min acclimation period under normoxia (room air) to establish a period of quiet and reliable breathing for baseline-ventilation levels (this is also indicated by a measured rejection index of 0 by the FinePointe Acquisition and Analysis Software). Mice were then exposed to hypoxia (12% or 8%  $O_2$ , with 0.05%  $CO_2$ , balanced with  $N_2$ ), hypoxia+hypercapnia (8%  $O_2$ , 5%  $CO_2$ , balanced with  $N_2$ ) or hypercapnia (21%  $O_2$ , 5%  $CO_2$ , balanced with  $N_2$ ) for 5 min or 10 min. Medical grade gas mixtures were chosen by switching a gas tap. The time for evacuation of the dead space and complete exchange of gas within the plethysmography chamber was 30 s. The duration of exposure to hypoxia quoted was the actual duration of hypoxia. Apnoea was defined as cessations of breathing greater than the average duration, including interval, of 2 successive breaths (600 ms) during normoxia, with a detection threshold of 0.25 mmHg (SD of noise). Breathing variability was assessed by Poincaré plots and by calculating the SD of inter-breath (BB) intervals. The breathing frequency, tidal volume and minute ventilation as derived by the FinePointe Software were also analysed for control and knockout mice. These parameters were measured as mean values taken over a 2 s breathing period and not on a breath-to-breath basis. The changes in breathing frequency, tidal volume and minute ventilation during hypoxia and/or hypercapnia were analysed as the percentage change from normoxia respective to each individual mouse. The peak of the augmenting phase was calculated from the peak value between 20–40 s of the hypoxic and/or hypercapnic exposure that coincides with the peak of the rising phase. The roll off period was calculated as the lowest value between 60–140 s of exposure and the sustained phase was calculated from the last 20 s in the plateaued phase. A large time range was required for selection of these points as experiments were performed on unrestrained and awake animals and periods of no movement, sniffing, or grooming, were only considered.

Apnoeas were excluded from all stated measures (mean  $\pm$  SEM) of breathing frequency, tidal volume and minute ventilation, i.e., all quoted values were derived from apnoea-free periods of ventilation.

**Statistics and reproducibility.** Statistical comparison was completed using GraphPad Prism 6 as follows: Calcium imaging data were assessed by Student's  $t$  test; Afferent discharge was assessed by single or 2 factor ANOVA with Bonferroni Dunn post hoc analysis and by Student's  $t$  test; Plethysmography was assessed by one-way ANOVA with Bonferroni multiple comparison's test and by Student's  $t$  test;  $p < 0.05$  was considered significant. For afferent discharge and plethysmography all quoted values are for ANOVA unless stated otherwise. All data are presented as mean  $\pm$  SEM. All responses studied were robust to inter-animal variability and highly reproducible. Replicates for calcium imaging on isolated type I cells refer to independent studies on 8–11 different cells from at least three (3) different mice. For afferent fibre discharge replicates refer to studies on 4–10

different carotid bodies, each from a different mouse. For plethysmography all measures reported are averages of  $n$  separate experiments on 4–7 mice spread over a six-month period from six months of age (C57/BL6, 5 mice; TH-Cre, 5 mice; *Lkb1* floxed, 4 mice; *Lkb1* knockout, 4 mice; CaMKK2 knockouts, 7 mice; AMPK- $\alpha$ 1/ $\alpha$ 2 floxed, 5 mice; AMPK- $\alpha$ 1/ $\alpha$ 2 floxed, 5 mice). To ensure as few mice as possible were used to determine differences by significance test, experiments were conducted and acquired data statistically assessed in stages by the variable criteria sequential stopping rule (SSR). In this way animal use was minimised, power maximised and the probability of type I errors kept constant.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

All data generated or analysed during this study are included in this published article (and its supplementary information files).

Received: 26 January 2022; Accepted: 14 June 2022;

Published online: 29 June 2022

## References

1. Teppema, L. J. & Dahan, A. The ventilatory response to hypoxia in mammals: mechanisms, measurement, and analysis. *Physiol. Rev.* **90**, 675–754 (2010).
2. Kumar, P. & Prabhakar, N. R. Peripheral chemoreceptors: function and plasticity of the carotid body. *Compr. Physiol.* **2**, 141–219 (2012).
3. Iturriaga, R., Alcayaga, J., Chappleau, M. W. & Somers, V. K. Carotid body chemoreceptors: physiology, pathology, and implications for health and disease. *Physiol. Rev.* **101**, 1177–1235 (2021).
4. Carling, D. AMPK signalling in health and disease. *Curr. Opin. Cell Biol.* **45**, 31–37 (2017).
5. Mahmoud, A. D. et al. AMP-activated protein kinase deficiency blocks the hypoxic ventilatory response and thus precipitates hypoventilation and apnea. *Am. J. Respir. Crit. Care Med.* **193**, 1032–43. (2016).
6. Mohr, M. A. et al. Quantification of periodic breathing in premature infants. *Physiol. Meas.* **36**, 1415–27. (2015).
7. Gauda, E. B., McLemore, G. L., Tolosa, J., Marston-Nelson, J. & Kwak, D. Maturation of peripheral arterial chemoreceptors in relation to neonatal apnoea. *Semin. Neonatol.* **9**, 181–194 (2004).
8. O'Halloran, K. D. Chronic intermittent hypoxia creates the perfect storm with calamitous consequences for respiratory control. *Respir. Physiol. Neurobiol.* **226**, 63–67 (2016).
9. Gozal, D. The energy crisis revisited: amp-activated protein kinase and the mammalian hypoxic ventilatory response. *Am. J. Respir. Crit. Care Med.* **193**, 945–946 (2016).
10. Boudeau, J. et al. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. *EMBO J.* **22**, 5102–5114 (2003).
11. Boudeau, J. et al. Analysis of the LKB1-STRAD-MO25 complex. *J. Cell Sci.* **117**, 6365–75. (2004).
12. Hawley, S. A. et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J. Biol.* **2**, 28 (2003).
13. Lizcano, J. M. et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *EMBO J.* **23**, 833–843 (2004).
14. Bright, N. J., Thornton, C. & Carling, D. The regulation and function of mammalian AMPK-related kinases. *Acta Physiol.* **196**, 15–26 (2009).
15. Gowans, G. J., Hawley, S. A., Ross, F. A. & Hardie, D. G. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. *Cell Metab.* **18**, 556–566 (2013).
16. Buckler, K. J. & Turner, P. J. Oxygen sensitivity of mitochondrial function in rat arterial chemoreceptor cells. *J. Physiol.* **591**, 3549–63. (2013).
17. Moreno-Dominguez, A. et al. Acute  $O_2$  sensing through HIF2alpha-dependent expression of atypical cytochrome oxidase subunits in arterial chemoreceptors. *Sci. Signal.* **13**, eaay9452 (2020).
18. Gonzalez, A., Hall, M. N., Lin, S. C. & Hardie, D. G. AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control. *Cell Metab.* **31**, 472–492 (2020).
19. Woods, A. et al. Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. *Cell Metab.* **2**, 21–33 (2005).
20. Pinkosky, S. L. et al. Long-chain fatty acyl-CoA esters regulate metabolism via allosteric control of AMPK beta1 isoforms. *Nat. Metab.* **2**, 873–881 (2020).

21. Zhang, C. S. et al. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. *Nature* **548**, 112–116 (2017).
22. Anderson, K. A. et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. *Cell Metab.* **7**, 377–88. (2008).
23. Sakamoto, K. et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. *EMBO J.* **24**, 1810–20. (2005).
24. Sakamoto, K. et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPK $\alpha$ 2 but not AMPK $\alpha$ 1. *Am. J. Physiol. Endocrinol. Metab.* **290**, E780–E788 (2006).
25. Terziyski, K. & Draganova, A. Central sleep apnea with cheyne-stokes breathing in heart failure - from research to clinical practice and beyond. *Adv. Exp. Med. Biol.* **1067**, 327–351 (2018).
26. Tatsumi, K., Hannhart, B., Pickett, C. K., Weil, J. V. & Moore, L. G. Effects of testosterone on hypoxic ventilatory and carotid body neural responsiveness. *Am. J. Respir. Crit. Care Med.* **149**, 1248–53. (1994).
27. Dasso, L. L., Buckler, K. J. & Vaughan-Jones, R. D. Interactions between hypoxia and hypercapnic acidosis on calcium signaling in carotid body type I cells. *Am. J. Physiol. Cell Mol. Physiol.* **279**, L36–L42 (2000).
28. Turner, P. J. and Buckler, K.J. Oxygen and mitochondrial inhibitors modulate both monomeric and heteromeric TASK-1 and TASK-3 channels in mouse carotid body type-1 cells. *J. Physiol.* **591**, 5977–5998 (2013).
29. Fernandez-Aguera, M. C. et al. Oxygen sensing by arterial chemoreceptors depends on mitochondrial complex I signaling. *Cell Metab.* **22**, 825–837 (2015).
30. Mulligan, E. & Lahiri, S. Separation of carotid body chemoreceptor responses to O<sub>2</sub> and CO<sub>2</sub> by oligomycin and by antimycin A. *Am. J. Physiol.* **242**, C200–C206 (1982).
31. Day, T. A. & Wilson, R. J. Brainstem PCO<sub>2</sub> modulates phrenic responses to specific carotid body hypoxia in an in situ dual perfused rat preparation. *J. Physiol.* **578**, 843–57. (2007).
32. Wilson, R. J. & Teppema, L. J. Integration of central and peripheral respiratory chemoreflexes. *Compr. Physiol.* **6**, 1005–41. (2016).
33. Hodson, E. J. et al. Regulation of ventilatory sensitivity and carotid body proliferation in hypoxia by the PHD2/HIF-2 pathway. *J. Physiol.* **594**, 1179–1195 (2016).
34. Li, P. et al. The peptidergic control circuit for sighing. *Nature* **530**, 293–297 (2016).
35. Smith, C. A., Engwall, M. J., Dempsey, J. A. & Bisgard, G. E. Effects of specific carotid body and brain hypoxia on respiratory muscle control in the awake goat. *J. Physiol.* **460**, 623–640 (1993).
36. Varas, R., Wyatt, C. N. & Buckler, K. J. Modulation of TASK-like background potassium channels in rat arterial chemoreceptor cells by intracellular ATP and other nucleotides. *J. Physiol.* **583**, 521–536 (2007).
37. Ortega-Saenz, P. & Lopez-Barneo, J. Physiology of the carotid body: from molecules to disease. *Annu Rev. Physiol.* **82**, 127–149 (2020).
38. Sacramento, J. F. et al. Contribution of adenosine and ATP to the carotid body chemosensory activity in ageing. *J. Physiol.* **597**, 4991–5008 (2019).
39. Murali, S. & Nurse, C. A. Purinergic signalling mediates bidirectional crosstalk between chemoreceptor type I and glial-like type II cells of the rat carotid body. *J. Physiol.* **594**, 391–406 (2016).
40. Jessen, N. et al. Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. *Biochim. Biophys. Acta* **1802**, 593–600 (2010).
41. Fu, A. et al. LKB1 couples glucose metabolism to insulin secretion in mice. *Diabetologia* **58**, 1513–1522 (2015).
42. Swisa, A. et al. Loss of liver kinase B1 (LKB1) in beta cells enhances glucose-stimulated insulin secretion despite profound mitochondrial defects. *J. Biol. Chem.* **290**, 20934–20946 (2015).
43. He, N. et al. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. *Proc. Natl Acad. Sci. USA* **114**, 12542–12547 (2017).
44. Conde, S. V., Monteiro, E. C., Rigual, R., Obeso, A. & Gonzalez, C. Hypoxic intensity: a determinant for the contribution of ATP and adenosine to the genesis of carotid body chemosensory activity. *J. Appl Physiol.* **112**, 2002–10. (2012).
45. Kim, D., Cavanaugh, E. J., Kim, I. & Carroll, J. L. Heteromeric TASK-1/TASK-3 is the major oxygen-sensitive background K<sup>+</sup> channel in rat carotid body glomus cells. *J. Physiol.* **587**, 2963–2975 (2009).
46. Pepper, D. R., Landauer, R. C. & Kumar, P. Postnatal development of CO<sub>2</sub>-O<sub>2</sub> interaction in the rat carotid body in vitro. *J. Physiol.* **485**, 531–541 (1995).
47. Koh, H. J. et al. Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. *Mol. Cell Biol.* **26**, 8217–8227 (2006).
48. Shaw, R. J. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science* **310**, 1642–1646 (2005).
49. Gan, B. et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. *Nature* **468**, 701–704 (2010).
50. Gurumurthy, S. et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. *Nature* **468**, 659–663 (2010).
51. Patel, K. et al. The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. *Nat. Commun.* **5**, 4535 (2014).
52. Choi, S., Lim, D. S. & Chung, J. Feeding and fasting signals converge on the LKB1-SIK3 pathway to regulate lipid metabolism in *Drosophila*. *PLoS Genet.* **11**, e1005263 (2015).
53. Evans, A. M. AMP-activated protein kinase and the regulation of Ca<sup>2+</sup> signalling in O<sub>2</sub>-sensing cells. *J. Physiol.* **574**, 113–23. (2006).
54. Curran, A. K. et al. Ventilatory responses to specific CNS hypoxia in sleeping dogs. *J. Appl Physiol.* **88**, 1840–1852 (2000).
55. Smith, C. A., Forster, H. V., Blain, G. M. & Dempsey, J. A. An interdependent model of central/peripheral chemoreception: evidence and implications for ventilatory control. *Respir. Physiol. Neurobiol.* **173**, 288–297 (2010).
56. Blain, G. M., Smith, C. A., Henderson, K. S. & Dempsey, J. A. Peripheral chemoreceptors determine the respiratory sensitivity of central chemoreceptors to CO(2). *J. Physiol.* **588**, 2455–71. (2010).
57. Ponikowski, P. et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. *Circulation* **104**, 544–549 (2001).
58. Hall, M. J. et al. Cycle length of periodic breathing in patients with and without heart failure. *Am. J. Respir. Crit. Care Med.* **154**, 376–381 (1996).
59. Topor, Z. L., Vasilakos, K., Younes, M. & Remmers, J. E. Model based analysis of sleep disordered breathing in congestive heart failure. *Respir. Physiol. Neurobiol.* **155**, 82–92 (2007).
60. Ross, F. A., MacKintosh, C. & Hardie, D. G. AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours. *FEBS J.* **283**, 2987–3001 (2016).
61. Bell, H. J., Azubike, E. & Haouzi, P. The “other” respiratory effect of opioids: suppression of spontaneous augmented (“sigh”) breaths. *J. Appl Physiol.* **111**, 1296–303. (2011).
62. Ikematsu, N. et al. Phosphorylation of the voltage-gated potassium channel Kv2.1 by AMP-activated protein kinase regulates membrane excitability. *Proc. Natl Acad. Sci. USA* **108**, 18132–18137 (2011).
63. Ross, F. A. et al. Selective expression in carotid body type I cells of a single splice variant of the large conductance calcium- and voltage-activated potassium channel confers regulation by AMP-activated protein kinase. *J. Biol. Chem.* **286**, 11929–11936 (2011).
64. Lipton, A. J. et al. S-nitrosothiols signal the ventilatory response to hypoxia. *Nature* **413**, 171–174 (2001).
65. Murphy, B. A., Fakira, K. A., Song, Z., Beuve, A. & Routh, V. H. AMP-activated protein kinase and nitric oxide regulate the glucose sensitivity of ventromedial hypothalamic glucose-inhibited neurons. *Am. J. Physiol. Cell Physiol.* **297**, C750–C758 (2009).
66. Chau, E. H., Lam, D., Wong, J., Mokhlesi, B. & Chung, F. Obesity hypoventilation syndrome: a review of epidemiology, pathophysiology, and perioperative considerations. *Anesthesiology* **117**, 188–205 (2012).
67. Ainslie, P. N., Lucas, S. J. & Burgess, K. R. Breathing and sleep at high altitude. *Respir. Physiol. Neurobiol.* **188**, 233–56. (2013).
68. Eichenwald E.C, Committee on F and Newborn AAOP. Apnea of prematurity. *Pediatrics*. 137 (2016).
69. Lantier, L. et al. AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity. *FASEB J.* **28**, 3211–3224 (2014).
70. Nurse, C. A. Synaptic and paracrine mechanisms at carotid body arterial chemoreceptors. *J. Physiol.* **592**, 3419–3426 (2014).
71. Hirooka, Y., Polson, J. W., Potts, P. D. & Dampney, R. A. Hypoxia-induced Fos expression in neurons projecting to the pressor region in the rostral ventrolateral medulla. *Neuroscience* **80**, 1209–24. (1997).
72. Lindeberg, J. et al. Transgenic expression of Cre recombinase from the tyrosine hydroxylase locus. *Genesis* **40**, 67–73 (2004).
73. Holmes, A. P., Turner, P. J., Buckler, K. J. & Kumar, P. Moderate inhibition of mitochondrial function augments carotid body hypoxic sensitivity. *Pflug. Arch.* **468**, 143–55. (2016).
74. Vidruk, E. H., Olson, E. B. Jr., Ling, L. & Mitchell, G. S. Responses of single-unit carotid body chemoreceptors in adult rats. *J. Physiol.* **531**, 165–170 (2001).
75. Holmes, A. P., Nunes, A. R., Cann, M. J. & Kumar, P. Ecto-5'-nucleotidase, adenosine and transmembrane adenylyl cyclase signalling regulate basal carotid body chemoafferent outflow and establish the sensitivity to hypercapnia. *Adv. Exp. Med. Biol.* **860**, 279–289 (2015).

### Acknowledgements

This work was primarily funded by a Wellcome Trust Programme Grant held by AME (WT081195MA), which also supported by subcontract the work of A.P.H and P.K. at the University of Birmingham. S.M. was supported by a University of Edinburgh Ph.D. studentship and then by a BHF Programme Grant held by AME (RG/12/14/29885). We thank Matthew Bailey for his kind support of blood gas measurements.

### Author contributions

A.M.E. conceived this study and developed the study plan in discussion with D.G.H. A.M.E. and S.M. wrote the manuscript and made Figs. 1–9. A.M.E. and S.M. developed



the conditional knockout mice. S.M. and A.D.M designed and validated primers and performed genotyping. M.J.S., A.D.M., S.M. and A.M.E. performed single-cell PCR. A.M.D., S.M. and A.M.E. performed plethysmography. S.M. and A.M.E. performed final analysis of respiratory data. S.M. and A.M.E. developed ROSA mice and performed confocal microscopy and immunocytochemistry. A.P.H. and P.K. performed afferent discharge and carried out data analysis blind, before final data compilation and interpretation by A.M.E. in discussion with S.M., A.P.H. and P.K. M.L.D., A.M.D. and C.P. carried out and performed initial acquisition and analysis of calcium imaging blind, which was later compiled, tested and interpreted by A.M.E. in discussion with S.M. All authors discussed their results and provided feedback on one or more drafts of this manuscript.

### Competing interests

The authors declare no competing interests.

### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s42003-022-03583-7>.

**Correspondence** and requests for materials should be addressed to A. Mark Evans.

**Peer review information** *Communications Biology* thanks Rodrigo Iturriaga and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Primary Handling Editors: Christopher Hine and Manuel Breuer. Peer reviewer reports are available.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022, corrected publication 2022